McKesson (NYSE:MCK) Releases FY 2027 Earnings Guidance

McKesson (NYSE:MCK) updated its FY 2027 earnings guidance on Thursday morning. The company provided EPS guidance of 44.200-45.000 for the period, compared to the consensus EPS estimate of 44.650. The company issued revenue guidance of -.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on MCK shares. Robert W. Baird set a $1,015.00 price target on shares of McKesson in a report on Thursday, August 6th. Morgan Stanley reiterated an “overweight” rating on shares of McKesson in a report on Friday, August 7th. Royal Bank Of Canada reissued a “sector perform” rating and set a $845.00 price objective on shares of McKesson in a research report on Monday, September 14th. Wells Fargo & Company boosted their target price on McKesson from $812.00 to $933.00 and gave the company an “equal weight” rating in a research note on Tuesday, August 11th. Finally, TD Cowen upped their target price on McKesson from $989.00 to $1,006.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Fourteen analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $973.44.

McKesson Stock Up 5.6%

Shares of MCK opened at $901.36 on Friday. The company’s fifty day moving average is $878.77 and its 200-day moving average is $833.11. McKesson has a 12 month low of $723.68 and a 12 month high of $999.00. The firm has a market cap of $105.09 billion, a price-to-earnings ratio of 24.12, a price-to-earnings-growth ratio of 1.70 and a beta of 0.30.

McKesson (NYSE:MCK) last released its quarterly earnings results on Wednesday, August 5th. The company reported $9.93 earnings per share for the quarter, beating analysts’ consensus estimates of $9.56 by $0.37. The business had revenue of $105.38 billion for the quarter, compared to the consensus estimate of $103.88 billion. McKesson had a net margin of 1.12% and a negative return on equity of 253.21%. McKesson’s revenue for the quarter was up 7.7% on a year-over-year basis. During the same quarter last year, the firm earned $8.26 EPS. McKesson has set its FY 2027 guidance at 44.200-45.000 EPS. As a group, research analysts predict that McKesson will post 44.64 earnings per share for the current fiscal year.

McKesson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, October 1st. Shareholders of record on Tuesday, September 1st were given a $0.94 dividend. This is an increase from McKesson’s previous quarterly dividend of $0.82. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend was Tuesday, September 1st. McKesson’s payout ratio is presently 10.06%.

Insider Transactions at McKesson

In other news, CEO Brian Tyler sold 8,463 shares of the stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $793.56, for a total transaction of $6,715,898.28. Following the transaction, the chief executive officer owned 5,919 shares of the company’s stock, valued at approximately $4,697,081.64. This represents a 58.84% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO B Jr sold 111 shares of the firm’s stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $891.45, for a total value of $98,950.95. Following the completion of the transaction, the chief accounting officer directly owned 521 shares in the company, valued at $464,445.45. The trade was a 17.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 8,875 shares of company stock worth $7,083,441. 0.06% of the stock is owned by corporate insiders.

Key McKesson News

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: McKesson agreed to extend its strategic pharmaceutical distribution relationship with CVS Health through June 2032. The extended contract supports recurring revenue and strengthens McKesson’s relationship with a major healthcare customer. McKesson Corporation Extends Pharmaceutical Distribution Agreement with CVS Health
• Positive Sentiment: The company reaffirmed fiscal 2027 adjusted EPS guidance of $44.20 to $45.00, broadly consistent with analyst expectations. Maintaining the outlook alongside the CVS agreement signaled continued confidence in operating momentum. McKesson Extends CVS Health Pact to 2032
• Positive Sentiment: Recent fiscal first-quarter results provided additional support: revenue reached approximately $105.4 billion, adjusted EPS was $9.93, and adjusted EPS increased 20% year over year. Investors may also be positioning ahead of the company’s next earnings report, scheduled for November 4, 2026.
• Neutral Sentiment: McKesson remains included among medical-supply stocks viewed as having potential as industry conditions improve. The company’s planned approximately $2.25 billion acquisition of Precision Medicine Group also expands its oncology and clinical research capabilities, though integration and deal execution remain considerations.
• Negative Sentiment: Data cited in recent coverage showed McKesson insiders made multiple open-market sales without reported purchases over the past six months. This may be a modest sentiment headwind, although insider transactions do not necessarily reflect management’s view of the company’s fundamentals.

About McKesson

McKesson Corporation (NYSE:MCK) is a healthcare services and information technology company that distributes pharmaceuticals, specialty drugs, medical supplies and other healthcare products. The company serves pharmacies, hospitals, health systems, physician practices, biopharma manufacturers and other healthcare providers, helping move products from manufacturers to patients and care settings.

McKesson’s principal operations include pharmaceutical distribution, medical-surgical supply distribution and technology-enabled services for pharmacies and providers.